{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T13:37:43Z","timestamp":1760189863701},"reference-count":22,"publisher":"Japanese Society for Lymphoreticular Tissue Research","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCEH","J Clin Exp Hematopathol"],"published-print":{"date-parts":[[2024]]},"DOI":"10.3960\/jslrt.23054","type":"journal-article","created":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T22:17:10Z","timestamp":1709072230000},"page":"59-64","source":"Crossref","is-referenced-by-count":3,"title":["A case of peripheral T-cell lymphoma in which therapy-related                    myelodysplastic syndrome developed and a second autologous transplantation was                    performed"],"prefix":"10.3960","volume":"64","author":[{"given":"Shun-ichiro","family":"Nakagawa","sequence":"first","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Nukii","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kanako","family":"Mochizuki","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akio","family":"Uchiyama","sequence":"additional","affiliation":[{"name":"Department of Pathology, Toyama Prefectural Central Hospital,                            Toyama, Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshinobu","family":"Maeda","sequence":"additional","affiliation":[{"name":"Division of Diagnostic Pathology, Toyama Red Cross Hospital,                            Toyama, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshiro","family":"Kurokawa","sequence":"additional","affiliation":[{"name":"Department of Hematology, Toyama Red Cross Hospital, Toyama,                            Japan,"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"2349","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1 Vose                            J,                                Armitage                            J,                                Weisenburger                            D. International                    T-Cell Lymphoma Project. International peripheral T-cell and natural                    killer\/T-cell lymphoma study: pathology findings and clinical outcomes. J Clin                    Oncol. 2008; 26: 4124-4130.","DOI":"10.1200\/JCO.2008.16.4558"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2 Bellei                            M,                                Foss                            FM,                                Shustov                            AR                    <i>et al.<\/i> The outcome of peripheral T-cell lymphoma patients                    failing first-line therapy: a report from the prospective, International T-Cell                    Project. Haematologica. 2018; 103: 1191-1197.","DOI":"10.3324\/haematol.2017.186577"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3 Cazzola                            M.                    Myelodysplastic Syndromes. N Engl J Med. 2020; 383: 1358-1374.","DOI":"10.1056\/NEJMra1904794"},{"key":"4","unstructured":"4 Swerdlow SH. International Agency for                    Research on C: WHO Classification of Tumours of Haematopoietic and Lymphoid                    Tissues. 4th ed, Lyon, International Agency for Research on Cancer.                    2017."},{"key":"5","doi-asserted-by":"crossref","unstructured":"5 Cheson                            BD,                                Fisher                            RI,                                Barrington                            SF                    <i>et al.<\/i> Recommendations for initial evaluation, staging, and                    response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano                    classification. J Clin Oncol. 2014; 32: 3059-3068.","DOI":"10.1200\/JCO.2013.54.8800"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6 . A predictive model for                    aggressive non-Hodgkin\u2019s lymphoma. N Engl J Med. 1993; 329:                    987-994.","DOI":"10.1056\/NEJM199309303291402"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7 Gallamini                            A,                                Stelitano                            C,                                Calvi                            R                    <i>et al.<\/i> Peripheral T-cell lymphoma unspecified (PTCL-U): a new                    prognostic model from a retrospective multicentric clinical study. Blood. 2004;                    103: 2474-2479.","DOI":"10.1182\/blood-2003-09-3080"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8 Ogura                            M,                                Kagami                            Y,                                Taji                            H                    <i>et al.<\/i> Pilot phase I\/II study of new salvage therapy (CHASE)                    for refractory or relapsed malignant lymphoma. Int J Hematol. 2003; 77:                    503-511.","DOI":"10.1007\/BF02986620"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9 Maeda                            S,                                Kagami                            Y,                                Ogura                            M                    <i>et al.<\/i> CD34+-selected autologous peripheral blood stem cell                    transplantation conditioned with total body irradiation for malignant lymphoma:                    increased risk of infectious complications. Int J Hematol. 2001; 74:                    214-221.","DOI":"10.1007\/BF02982008"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10 Ogura                            M,                                Yamamoto                            K,                                Morishima                            Y                    <i>et al.<\/i> R\u2010High\u2010CHOP\/CHASER\/LEED with autologous stem cell                    transplantation in newly diagnosed mantle cell lymphoma: JCOG0406 STUDY. Cancer                    Sci. 2018; 109: 2830-2840.","DOI":"10.1111\/cas.13719"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11 Sorror                            ML,                                Maris                            MB,                                Storb                            R                    <i>et al.<\/i> Hematopoietic cell transplantation (HCT)-specific                    comorbidity index: a new tool for risk assessment before allogeneic HCT. Blood.                    2005; 106: 2912-2919.","DOI":"10.1182\/blood-2005-05-2004"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12 Greenberg                            P,                                Cox                            C,                                LeBeau                            MM                    <i>et al.<\/i> International scoring system for evaluating prognosis in                    myelodysplastic syndromes. Blood. 1997; 89: 2079-2088.","DOI":"10.1182\/blood.V89.6.2079"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13 Greenberg                            PL,                                Tuechler                            H,                                Schanz                            J                    <i>et al.<\/i> Revised international prognostic scoring system for                    myelodysplastic syndromes. Blood. 2012; 120: 2454-2465.","DOI":"10.1182\/blood-2012-03-420489"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14 Mak                            V,                                Hamm                            J,                                Chhanabhai                            M                    <i>et al.<\/i> Survival of patients with peripheral T-cell lymphoma                    after first relapse or progression: spectrum of disease and rare long-term                    survivors. J Clin Oncol. 2013; 31: 1970-1976.","DOI":"10.1200\/JCO.2012.44.7524"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15 Maurer                            MJ,                                Ellin                            F,                                Srour                            L                    <i>et al.<\/i> International assessment of event-free survival at 24                    months and subsequent survival in peripheral T-cell lymphoma. J Clin Oncol.                    2017; 35: 4019-4026.","DOI":"10.1200\/JCO.2017.73.8195"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16 Horwitz                            SM,                                Advani                            RH,                                Bartlett                            NL                    <i>et al.<\/i> Objective responses in relapsed T-cell lymphomas with                    single-agent brentuximab vedotin. Blood. 2014; 123: 3095-3100.","DOI":"10.1182\/blood-2013-12-542142"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17 Kalaycio                            M,                                Rybicki                            L,                                Pohlman                            B                    <i>et al.<\/i> Risk factors before autologous stem-cell transplantation                    for lymphoma predict for secondary myelodysplasia and acute myelogenous                    leukemia. J Clin Oncol. 2006; 24: 3604-3610.","DOI":"10.1200\/JCO.2006.06.0673"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18 Yamasaki                            S,                                Suzuki                            R,                                Hatano                            K                    <i>et al.<\/i> Therapy-related acute myeloid leukemia and                    myelodysplastic syndrome after hematopoietic cell transplantation for lymphoma.                    Bone Marrow Transplant. 2017; 52: 969-976.","DOI":"10.1038\/bmt.2017.52"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19 Slovak                            ML,                                O\u2019Donnell                            M,                                Smith                            DD,                                Gaal                            K. Does MDS with                    der(1;7)(q10;p10) constitute a distinct risk group? A retrospective single                    institutional analysis of clinical\/pathologic features compared to -7\/del(7q)                    MDS. Cancer Genet Cytogenet. 2009; 193: 78-85.","DOI":"10.1016\/j.cancergencyto.2009.04.013"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20 Sanada                            M,                                Uike                            N,                                Ohyashiki                            K                    <i>et al.<\/i> Unbalanced translocation der(1;7)(q10;p10) defines a                    unique clinicopathological subgroup of myeloid neoplasms. Leukemia. 2007; 21:                    992-997.","DOI":"10.1038\/sj.leu.2404619"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21 Lisenko                            K,                                Pavel                            P,                                Kriegsmann                            M                    <i>et al.<\/i> Storage duration of autologous stem cell preparations                    has no impact on hematopoietic recovery after transplantation. Biol Blood Marrow                    Transplant. 2017; 23: 684-690.","DOI":"10.1016\/j.bbmt.2016.12.631"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22 Yanada                            M,                                Tsuzuki                            M,                                Fujita                            H                    <i>et al.<\/i> Phase 2 study of arsenic trioxide followed by autologous                    hematopoietic cell transplantation for relapsed acute promyelocytic leukemia.                    Blood. 2013; 121: 3095-3102.","DOI":"10.1182\/blood-2012-11-466862"}],"container-title":["Journal of Clinical and Experimental Hematopathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/1\/64_23054\/_pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,30]],"date-time":"2024-03-30T05:44:56Z","timestamp":1711777496000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/jslrt\/64\/1\/64_23054\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024]]},"references-count":22,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.3960\/jslrt.23054","relation":{},"ISSN":["1346-4280","1880-9952"],"issn-type":[{"value":"1346-4280","type":"print"},{"value":"1880-9952","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024]]},"article-number":"23054"}}